Evaluate the Safety and Clinical Activity of HH2853

This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous 28-day treatment cycle.

Trial Details

NCT ID
NCT04390737
Phase
PHASE1 / PHASE2
Sponsor
Haihe Biopharma Co., Ltd.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • HH2853 Tablets
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • San Antonio, Texas, United States|29.42412,-98.49363
  • Hefei, Anhui, China|31.86389,117.28083

Key Eligibility Criteria

  • Provided signed written informed consent prior to initiation of any study-related procedures;
  • Males and females ≥ 18years of age at the time of consent are obtained (or meet the country's regulatory defined adult legal age);
  • Tumor type criteria:
  • The specific requirements for specific subtypes of recurrent/refractory non Hodgkin's lymphoma (NHL) confirmed by histology are as follows:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →